Field Guide · Deconstructed
Red and near-infrared light — photobiomodulation — is one of the gentler items on the “what hasn’t been tried” menu: a child sits near a panel or wears a cap, and specific wavelengths of light are absorbed by the mitochondria to (in theory) lift cellular energy and lower inflammation. Here’s the straight version: the mechanism is real and interesting, the human evidence in autism is early and thin, and there is essentially no PANS research — so it’s a low-risk thing to explore with eyes open, not a cure.
I walked this part of the labyrinth myself — knocked on the doors, read the research, and came back with the map. You don’t have to find the way out alone.
Photobiomodulation (PBM) — the technical name for “red light therapy” — uses low-power red (around 630–660 nm) and near-infrared (around 810–850 nm) light. It is not a heat lamp. The wavelengths are chosen because they’re absorbed by cytochrome c oxidase, an enzyme in the mitochondria — the cell’s energy plant. The proposed downstream effects are the reason families fighting a brain-based condition pay attention:
The mental model: like HBOT, this isn’t a move that kills something. It’s a support-and-calm step that aims to help cells make energy and quiet inflammation — it belongs in the “calm the brain / support recovery” column, paired with the treatments doing the actual killing, not instead of them.
This is the part that gets oversold. Read it carefully. The mechanism is genuinely interesting; the human clinical evidence is thin, and for PANS specifically it is essentially absent.
A small number of pilot studies of transcranial photobiomodulation in children with autism have reported improvements in irritability, attention, sleep, and behavior on parent-rated scales. These are early-phase, small, and some are industry-linked or open-label — promising enough to take seriously, not strong enough to call proven. The broader PBM literature for brain conditions (traumatic brain injury, stroke recovery, depression) is more developed and lends mechanistic plausibility, but those are different conditions in adults.
The label: low-risk, early-evidence, worth-exploring-with-eyes-open. The mechanism (mitochondrial support, anti-inflammatory) is solid in the lab; the autism behavioral payoff is preliminary; the PANS payoff is unstudied. This is a reasonable thing to trial as a gentle adjunct — never a reason to delay treating an active infection, and never sold as a cure.
Read this as “what the research and clinics typically use,” not a prescription. There is no FDA-approved PBM protocol for autism or PANS. The universal rule holds: start gentle, go slow, one new thing at a time, and read direction over weeks.
| Variable | Typical range | Why |
|---|---|---|
| Wavelength | Red ~630–660 nm + near-infrared ~810–850 nm | These are the wavelengths best absorbed by mitochondria; near-infrared penetrates deeper for transcranial use. |
| Form factor | Panel, handheld, or transcranial LED cap/helmet | Panels for body/general use; caps for brain-focused (transcranial) protocols. |
| Session length | A few minutes up to ~20 min | Short sessions; more is not better because of the biphasic dose response. |
| Cadence | Several times a week over weeks | Effects (if any) accumulate; judge direction over weeks, not one session. |
The pattern to notice: PBM is dosed in a narrow window — not “more is better.” Don’t stack it with three other new things at once or you won’t know what did what, and don’t judge it after a single session. A transcranial protocol aimed at the brain should be run with a knowledgeable provider, not improvised.
The reassuring part: topical red/near-infrared light is among the lower-risk things on this map. It’s non-invasive, and the “off switch” is simply turning it off — there’s no lingering agent. Still, a few real precautions:
The one rule that matters: red light therapy is a supportive layer. If a child has an active infection or immune attack driving PANS, light over the head does not treat it. Run this alongside the root-cause workup, never as a substitute — and walk away from anyone who tells you it can cure autism or PANS, or that it replaces real medical care.
Polish and price tell you nothing. What does: behavior and incentives. Red light is a real tool sold in a market full of overclaiming, so judge the seller, not the shine.
Wondering whether red light therapy even belongs on your child’s table? Plan B reads your child’s history, symptoms, and any labs together and tells you honestly where a gentle layer like this fits — and what the higher-priority root-cause work should be. Your first Synthesis is free.
Start your free Synthesis → Parent education, not medical advice. You stay in charge.Red light therapy rests on a real, interesting mechanism — light absorbed by mitochondria to support energy and quiet inflammation. But the human evidence in autism is early and limited, and for PANS there is essentially none. So it’s a low-risk option on the “what hasn’t been tried” menu, labeled honestly as early-evidence and supportive. If it’s on your table: keep doses in the sensible window, protect the eyes, go slow with a sensitive kid, and run it alongside the root-cause work — never instead of it, and never sold as a cure. Children labeled autistic deserve respect for who they are; this is about looking for treatable medical contributors to suffering, not “fixing” a child. Parent education, not medical advice — bring it to your team as questions.
Plan B does not partner with drug companies or doctors, and we never endorse anyone whose healing isn’t verified by families. We show you the options and how to vet them yourself — and we’re building parent verification: look up a clinic or device before you trust it. Universal bad reviews? Skip.